Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
Authors
Paul P. Tak (ORCID: https://orcid.org/0000-0002-3532-5409)
Murray B. Urowitz (ORCID: https://orcid.org/0000-0001-7506-9166)
Ronald van Vollenhoven (ORCID: https://orcid.org/0000-0001-6438-8663)
Don Shanahan
Mary Oldham
Cornelia F Allaart (ORCID: https://orcid.org/0000-0003-4815-2110)
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
Paul P. Tak, Murray B. Urowitz, Ronald van Vollenhoven, Don Shanahan et al.
Citations
42 citations
Journal
Annals of the Rheumatic Diseases
Topics
Systemic Lupus Erythematosus Research
Field-Weighted Citation Impact (FWCI)
18.33
article
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
Paul P. Tak, Murray B. Urowitz, Ronald van Vollenhoven, Don Shanahan, Mary Oldham, Cornelia F Allaart, Cynthia Aranow, Yun Irene Gregan, W. Winn Chatham, James Groark, Kenneth L. Clark, Robert B. Henderson, David A. Roth, Zahir Amoura, Patricia C Cagnoli, Mark Daniels, Ian N Bruce, André van Maurik, Josephine C Ocran-Appiah, Richard Alan Furie, Y K Onno Teng, Norma Lynn Fox
article en
42 citations
Abstract
No abstract available for this paper.
Publication Tag
Annals of the Rheumatic DiseasesVol. 83(11)
Institutions
Northwell Health (US), Feinstein Institute for Medical Research (US), Inserm (FR), University of Toronto (CA), University of Michigan (US), Toronto Western Hospital (CA), Manchester Academic Health Science Centre (GB), Leiden University Medical Center (NL), Age UK (GB), University of Manchester (GB), University of Alabama at Birmingham (US), Sorbonne Université (FR), Assistance Publique – Hôpitaux de Paris (FR), GlaxoSmithKline (United States) (US), Centre d'Immunologie et des Maladies Infectieuses (FR)